265,468 Shares in Hims & Hers Health, Inc. (NYSE:HIMS) Bought by Salem Investment Counselors Inc.

Salem Investment Counselors Inc. bought a new stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 265,468 shares of the company's stock, valued at approximately $7,845,000. Salem Investment Counselors Inc. owned 0.12% of Hims & Hers Health as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also made changes to their positions in HIMS. Blume Capital Management Inc. increased its position in shares of Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after buying an additional 600 shares in the last quarter. Smartleaf Asset Management LLC increased its position in shares of Hims & Hers Health by 4,415.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock valued at $36,000 after buying an additional 1,413 shares in the last quarter. Summit Securities Group LLC purchased a new position in shares of Hims & Hers Health in the fourth quarter valued at $38,000. UMB Bank n.a. increased its position in Hims & Hers Health by 247.5% during the 1st quarter. UMB Bank n.a. now owns 1,310 shares of the company's stock worth $39,000 after purchasing an additional 933 shares in the last quarter. Finally, Fifth Third Bancorp increased its position in Hims & Hers Health by 165.4% during the 1st quarter. Fifth Third Bancorp now owns 1,542 shares of the company's stock worth $46,000 after purchasing an additional 961 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company's stock.

Insiders Place Their Bets

In other news, CEO Andrew Dudum sold 128,127 shares of the business's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $33.98, for a total value of $4,353,755.46. Following the completion of the sale, the chief executive officer now directly owns 173,655 shares in the company, valued at approximately $5,900,796.90. The trade was a 42.46% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Patrick Harrison Carroll sold 23,287 shares of the business's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $34.31, for a total value of $798,976.97. Following the completion of the sale, the insider now owns 209,661 shares of the company's stock, valued at $7,193,468.91. This trade represents a 10.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 628,067 shares of company stock worth $25,832,688 in the last three months. 13.71% of the stock is owned by insiders.

Hims & Hers Health Price Performance

NYSE:HIMS traded down $1.82 during mid-day trading on Friday, reaching $55.33. The company's stock had a trading volume of 26,342,229 shares, compared to its average volume of 21,103,240. The stock has a market cap of $12.38 billion, a P/E ratio of 125.75 and a beta of 2.09. Hims & Hers Health, Inc. has a twelve month low of $13.47 and a twelve month high of $72.98. The company's fifty day simple moving average is $44.50 and its two-hundred day simple moving average is $37.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.08. The business had revenue of $586.01 million for the quarter, compared to analyst estimates of $535.21 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company's revenue was up 110.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.05 EPS. Sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Analysts Set New Price Targets

HIMS has been the subject of a number of recent research reports. Morgan Stanley reiterated an "equal weight" rating and set a $40.00 price objective on shares of Hims & Hers Health in a research report on Wednesday. Piper Sandler reiterated a "neutral" rating and set a $39.00 price objective (up previously from $35.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. TD Cowen cut Hims & Hers Health from a "buy" rating to a "hold" rating and dropped their price objective for the stock from $44.00 to $30.00 in a research report on Tuesday, April 29th. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Hims & Hers Health in a research report on Wednesday, May 7th. Finally, Wall Street Zen cut Hims & Hers Health from a "buy" rating to a "hold" rating in a research report on Saturday, June 7th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat.com, Hims & Hers Health presently has a consensus rating of "Hold" and an average target price of $38.00.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.